Eli Lilly and Co. just hit another bump in the road in its quest to push deeper into treatments for skin diseases, the third setback this year for the Indianapolis-based drugmaker from the U.S Food and Drug Administration.
Read More
The FDA cleared the COVID-19 booster tweaks without requiring human test results—just like it approves yearly changes to flu vaccines.
Read More
The federal government has purchased more than 170 million doses of the updated boosters, and doses began shipping last week, following authorization by the Food and Drug Administration.
Read More
COVID-19 vaccine makers are studying updated boosters that might be offered in the fall to better protect people against future coronavirus surges.
Read More
Lilly’s newest obesity and diabetes medicines, widely known as GLP-1 drugs, are drawing rave reviews from doctors, researchers and patients for their ability to safely and effectively control blood sugar and take off weight.
Christopher Wray’s statement follows a Department of Energy analysis for a new government-wide intelligence assessment that a lab accident in Wuhan was most likely responsible for the deadly pandemic.
The test is the first over-the-counter test distributed in the U.S. by Roche Diagnostics, which has its North American headquarters in Indianapolis.
The IU School of Medicine announced won a five-year, $48.8 million grant from the National Institute on Aging, a division of the National Institutes of Health, to create in mice genetic mutations similar to those found in people with late-onset Alzheimer’s.
Between 7 million and 23 million Americans—including 1 million who can no longer work—are suffering from the long-term effects of infection with the virus, according to government estimates.
The FDA approved the drug from Amylyx Pharmaceuticals based on results from one small, mid-stage study in which patients with the debilitating disease appeared to progress more slowly and survive several months longer.
The new estimate is a dramatic increase from the roughly $16 billion in potential fraud identified a year ago, and it illustrates the immense task still ahead of Washington as it seeks to pinpoint the losses, recover the funds and hold criminals accountable.
CDC’s advisers deemed the updated injections the best option considering the U.S. still is experiencing tens of thousands of COVID-19 cases and about 500 deaths every day—even before an expected new winter wave.
Pfizer asked U.S. regulators Monday to authorize its combination COVID-19 vaccine that adds protection against the newest omicron relatives—a key step toward opening a fall booster campaign.
The research, published online Tuesday by the journal Science, shows that the Huanan Seafood Wholesale Market was likely the early epicenter of the scourge that has now killed nearly 6.4 million people around the world.
Novavax makes a more traditional type of shot than the three other COVID-19 vaccines available for use in the U.S.—and one that’s already available in Europe and multiple other countries.
The surge reversed years of progress fighting one of the gravest public health challenges in modern medicine, according to a new analysis released Tuesday by the Centers for Disease Control and Prevention.
Officials warn of a possible fall or winter wave—perhaps as many as 100 million infections in the United States—that could again flood hospitals with COVID patients.
The FDA is considering ordering a recipe change for the vaccines made by both Pfizer and rival Moderna in hopes that modified boosters could better protect against another COVID surge expected this fall and winter.
The researchers used data from 185 countries to estimate that vaccines prevented 4.2 million COVID-19 deaths in India, 1.9 million in the United States, 1 million in Brazil, 631,000 in France and 507,000 in the United Kingdom.
The patient’s test at the Indiana Department of Health Laboratories on Saturday was positive and a confirmatory test is pending at the Centers for Disease Control and Prevention, state health officials said.
The advance toward a vaccine for infants, toddlers and preschoolers has been an achingly slow and incremental process, with pediatricians and families waiting for an opportunity to vaccinate young children.
Administration officials say they’re running low on money to stock up on, or even begin to order, the latest vaccines, tests and treatments. Also lacking are funds to reimburse doctors treating uninsured patients and to help poor countries control the pandemic.
Despite a nationwide surge in COVID-19 cases, deaths from the virus have remained largely stable over the past eight weeks.
This week, the Centers for Disease Control and Prevention released new estimates of the syndrome’s toll in the United States, suggesting it affects one in five adults younger than 65 who had COVID, and one in four of those aged 65 and older.
